Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study

Janis M. Taube(Bloomberg (United States)), Cliff C. Hoyt(Akoya Biosciences (United States))
Journal for ImmunoTherapy of Cancer
July 1, 2021
10.1136/jitc-2020-002197
Cited by 109

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k